secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2026-08-28T21:06:48+00:00
Accession:  0001493152-26-040645
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics receives NYSE American delisting notice; equity $3.7M below needed thresholds
--------------------------------------------------------------------------------

- NYSE American deficiency letter dated Aug 26, 2026 citing non-compliance with Sections 1003(a)(ii)/(iii); equity $3.7M at June 30, 2026 vs $4M/$6M minimums.
- Compliance plan due Sept 25, 2026; cure period through Feb 25, 2028; OGEN shares get '.BC' (below compliance) designation.
- Phase IIa trial for ONP-002: 9 participants dosed across 3 Australian sites (Alfred Health, Mackay, Royal Adelaide Hospital).
- FDA Type B meeting responses received for July 2026 package; IND submission still targeted by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315226040645/0001493152-26-040645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315226040645/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-040645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer